First Trust Advisors LP Sells 89,600 Shares of Illumina, Inc. $ILMN

First Trust Advisors LP trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 16.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 464,958 shares of the life sciences company’s stock after selling 89,600 shares during the period. First Trust Advisors LP owned 0.30% of Illumina worth $44,157,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its stake in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the last quarter. Quent Capital LLC acquired a new stake in Illumina in the 3rd quarter valued at about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in Illumina in the 3rd quarter valued at about $33,000. Mather Group LLC. bought a new position in Illumina during the third quarter worth about $46,000. Finally, SJS Investment Consulting Inc. grew its holdings in Illumina by 13,225.0% during the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 529 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of several research analyst reports. Canaccord Genuity Group upped their price objective on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. reduced their target price on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Finally, Stifel Nicolaus raised their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average target price of $129.69.

Illumina Trading Down 0.7%

ILMN stock opened at $121.50 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company’s 50-day simple moving average is $133.77 and its 200 day simple moving average is $119.71. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The company has a market capitalization of $18.58 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.34 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.